NCT04685070 2024-08-14
Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Active not recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Zhejiang Cancer Hospital